SciClone To Present At 2015 Aegis Capital Growth Conference On October 9th

Sep 30, 2015, 06:00 ET from SciClone Pharmaceuticals, Inc.

FOSTER CITY, Calif., Sept. 30, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 2015 Aegis Capital Growth Conference at 11:25 am PT on Friday, October 9, 2015, at The Encore at Wynn Las Vegas.  

To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com, under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live events.

About SciClone

SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially.  Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.

Corporate Contacts


Wilson W. Cheung  

Jane Green  

Chief Financial Officer       

Investors/Media

650.358.3434         

650.358.1447

wcheung@sciclone.com   

jgreen@sciclone.com

Logo - http://photos.prnewswire.com/prnh/20150722/240358LOGO

 

SOURCE SciClone Pharmaceuticals, Inc.



RELATED LINKS

http://www.sciclone.com